KarenLTedescoMD

Oncology • Amsterdam, NY

Physician

Join to view full profile

Dr. Tedesco is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tedesco's full profile

Already have an account?

Office
1700 Riverfront Ctr
Amsterdam, NY 12010
Phone+1 518-843-0020

Fax+1 518-843-0023

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
University of MichiganResidency, Internal Medicine, 1998 - 2001
SUNY Upstate Medical UniversityClass of 1998

Certifications & Licensure

NY State Medical License 2004 - 2025
TN State Medical License 2001 - 2004
MI State Medical License 1998 - 2001
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01
Completed
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer Start of enrollment: 2019 Jun 11
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

15 citations
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.
Costanza Paoletti, Meredith M. Regan, Samuel M. Niman, Emily M. Dolce, Elizabeth P. Darga
NPJ Breast Cancer. 2021-06-11
4 citations
Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.
John W. Smith, Amy Irwin, Lori Jensen, Karen L. Tedesco, Soamnauth Misir
Clinical Breast Cancer. 2020-04-01
9 citations
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Jeffrey L. Vacirca, Arlene Chan, Klára Mezei, Clarence S. Adoo, Zsuzsanna Pápai
Cancer Medicine. 2018-05-01